SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. Thanks to the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages, despite the COVID-19 pandemic possibly having impacted these numbers (not yet quantified). In recent years, locoregional and systemic therapies are increasingly being directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody-drug conjugates have also improved outcomes in some patient subgroups. This clinical practice guideline is based on a systematic review of relevant studies and on the consensus of experts from GEICAM, SOLTI, and SEOM.

Automated summary

Breast cancer is the main cause of cancer in women in Spain, with a rapidly increasing annual incidence. Despite the potential impact of the COVID-19 pandemic on screening programs (not yet quantified), almost 90% of breast cancer cases are detected early and can be potentially cured. New diagnostic tools have improved the balance between toxicity and clinical benefit in locoregional and systemic therapies, and new therapeutic strategies such as immunotherapy, targeted drugs, and antibody-drug conjugates have improved outcomes in certain patient subgroups.